60 Degrees Pharmaceuticals, Inc. Common Stock (NASDAQ:SXTP) — Market Cap & Net Worth
Market Cap & Net Worth: 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP)
60 Degrees Pharmaceuticals, Inc. Common Stock (NASDAQ:SXTP) has a market capitalization of $4.06 Million ($4.06 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28965 globally and #5863 in its home market, demonstrating a 16.55% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 60 Degrees Pharmaceuticals, Inc. Common Stock's stock price $1.62 by its total outstanding shares 2636788 (2.64 Million). Review SXTP current and long-term liabilities to assess the company's total debt and financial obligations.
60 Degrees Pharmaceuticals, Inc. Common Stock Market Cap History: 2023 to 2026
60 Degrees Pharmaceuticals, Inc. Common Stock's market capitalization history from 2023 to 2026. Data shows change from $32.27 Million to $4.27 Million (-70.13% CAGR).
Index Memberships
60 Degrees Pharmaceuticals, Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #856 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2720 of 3165 |
Weight: 60 Degrees Pharmaceuticals, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
60 Degrees Pharmaceuticals, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 60 Degrees Pharmaceuticals, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.33x
60 Degrees Pharmaceuticals, Inc. Common Stock's market cap is 1.33 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $32.27 Million | $253.57K | -$3.77 Million | 127.28x | N/A |
| 2024 | $3.40 Million | $607.57K | -$7.95 Million | 5.60x | N/A |
| 2025 | $1.34 Million | $1.01 Million | -$7.37 Million | 1.33x | N/A |
Competitor Companies of SXTP by Market Capitalization
Companies near 60 Degrees Pharmaceuticals, Inc. Common Stock in the global market cap rankings as of June 18, 2026.
Key companies related to 60 Degrees Pharmaceuticals, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
60 Degrees Pharmaceuticals, Inc. Common Stock Historical Marketcap From 2023 to 2026
Between 2023 and today, 60 Degrees Pharmaceuticals, Inc. Common Stock's market cap moved from $32.27 Million to $ 4.27 Million, with a yearly change of -70.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.27 Million | +218.71% |
| 2025 | $1.34 Million | -60.60% |
| 2024 | $3.40 Million | -89.46% |
| 2023 | $32.27 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of 60 Degrees Pharmaceuticals, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.06 Million USD |
| MoneyControl | $4.06 Million USD |
| MarketWatch | $4.06 Million USD |
| marketcap.company | $4.06 Million USD |
| Reuters | $4.06 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About 60 Degrees Pharmaceuticals, Inc. Common Stock
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications… Read more